Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine
Following an influenza challenge, the modRNA vaccine was associated with greater VE and reduced VL compared with the control, without any serious adverse events. (Funded by hVIVO and Pfizer; clinical trial registration number, ISRCTN13789612.).
Authors
- Agnieszka Zareba (ORCID: https://orcid.org/0000-0003-4118-6879)
- Annaliesa S. Anderson (ORCID: https://orcid.org/0000-0002-6413-1718)
- Kingsley Eze (ORCID: https://orcid.org/0000-0002-6764-0710)
- Alex Mann (ORCID: https://orcid.org/0000-0002-3744-4604)
- K.S. Wolfe (ORCID: https://orcid.org/0000-0001-5565-3496)
- Emily Gomme
- Sarah Mirza
- Melissa Bevan
- Anita Geevarughese
- Kevin Yi
- Alejandra Gurtman (ORCID: https://orcid.org/0000-0003-3469-1201)
- Pascale V. Nantermet
- Kelly Lindert
- Teresa Hauguel
- Andrew Catchpole
- Pirada Suphaphiphat Allen (ORCID: https://orcid.org/0000-0002-2324-5751)
- Pratiksha Dokhe
Institutions
- Zimmer Biomet (Netherlands) (NL)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- hVIVO (United Kingdom) (GB)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1056/evidoa2500087
- Citations
- 2
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71